Latest Conference Articles

February 10th 2020, 10:11pm

PER® Winter Lung Cancer Conference

Julie R. Brahmer, MD, discusses the impact of osimertinib in EGFR-mutant non–small cell lung cancer, ongoing research with the agent, and the importance of molecular testing.

February 10th 2020, 9:34pm

PER® Winter Lung Cancer Conference

Treatment with osimertinib in the frontline has been the standard of care for patients with EGFR-mutant non–small cell lung cancer since the pivotal FLAURA trial.

February 10th 2020, 8:30pm

SGO Winter Meeting

Floor J. Backes, MD, discusses the role of PARP inhibitors as treatment of patients with ovarian cancer and her experience with these agents, such as rucaparib.

February 10th 2020, 8:03pm

SGO Winter Meeting

Angeles Alvarez Secord, MD, discusses a presentation from the 2020 SGO Winter Meeting that focused on assistance with the financial burden associated with PARP inhibitors in patients with ovarian cancer.

February 10th 2020, 1:48am

PER® Winter Lung Cancer Conference

Significant research advances in targeted therapy and immunotherapy within the past years have created a more personalized approach to treatment for patients with advanced non–small cell lung cancer.

February 10th 2020, 1:36am

SGO Winter Meeting

Three pivotal clinical trials evaluating PARP inhibitors have significantly impacted the treatment of patients with newly diagnosed ovarian cancer.

February 9th 2020, 10:15pm

PER® Winter Lung Cancer Conference

Based on available data, treatment is not that obvious for patients with metastatic non–small cell lung cancer who are tolerating treatment well and have either a complete or partial response to therapy.

February 9th 2020, 10:15pm

SGO Winter Meeting

Ian Hagemann, MD, PhD, discusses the main take home from his presentation at the 2020 SGO Winter Meeting.

February 9th 2020, 10:11pm

SGO Winter Meeting

Julia Fehniger, MD, shares her thoughts on the development of PARP inhibitors in ovarian cancer and expansion into other tumor types.

February 9th 2020, 9:40pm

SGO Winter Meeting

With few chemotherapy options available for patients with cervical cancer, R. Wendel Naumann, MD, said that immunotherapy represents an attractive treatment option in the landscape.

February 9th 2020, 9:35pm

PER® Winter Lung Cancer Conference

Suresh S. Ramalingam, MD, FASCO, discusses the current treatment parameters for osimertinib in EGFR-mutant non–small cell lung cancer and ongoing research with the agent.

February 9th 2020, 9:31pm

PER® Winter Lung Cancer Conference

Gilberto De Lima Lopes, MD, discusses the standard of care for pembrolizumab in patients with metastatic lung cancer.

February 9th 2020, 8:22pm

PER® Winter Lung Cancer Conference

The standard of care for patients with small cell lung cancer has been trapped in a period of stagnation for the past several decades.

February 9th 2020, 4:15am

PER® Winter Lung Cancer Conference

The potential therapeutic benefits of immune checkpoint inhibitors as monotherapy as well as in combination with chemotherapy for patients with non–small cell lung cancer depend greatly on the timing of treatment initiation. However, for patients with EGFR, ALK, and other actionable mutations, identifying the optimal combination is a hurdle.

February 9th 2020, 2:03am

SGO Winter Meeting

Angeles Alvarez Secord, MD, gynecologic oncologist, Duke Cancer Center, discusses the role of PARP inhibitors in ovarian cancer based on their current indications in the treatment landscape.

February 9th 2020, 2:01am

SGO Winter Meeting

Carrie L. Langstraat, MD, gynecologic oncologist, Mayo Clinic, discusses the role of sentinel lymph nodes in patients with endometrial cancers.

February 9th 2020, 1:20am

SGO Winter Meeting

Floor J. Backes, MD, discusses the latest advancements made in the treatment of patients with ovarian cancer and the ongoing research efforts that are being made with novel combinations.

February 8th 2020, 11:59pm

PER® Winter Lung Cancer Conference

Advancements in the prevention and treatment of patients with lung cancer have picked up momentum over the past decade and now is the time to build on that progress according to Suresh S. Ramalingam, MD, FASCO.

February 8th 2020, 10:18pm

SGO Winter Meeting

Tumors from a significant percentage of patients with endometrial cancer at NYU Langone Health’s Perlmutter Cancer Center were found to have BRCA1/2 somatic mutations.

February 8th 2020, 8:36pm

PER® Winter Lung Cancer Conference

Jamie E. Chaft, MD, discusses the rise of immunotherapy in lung cancer and research with this treatment modality that is on the horizon.